Death rates from heart disease have fallen by almost 5x since the 1950’s.
We’ve gone from over 500 deaths per 100,000 in 1950 down to almost 100 in 2020:
↪ US heart disease death rate fell about 5-fold, from over 500 to almost 100 per 100,000
The drops strongly correlate with the introduction of cholesterol lowering drugs, and with the steady reduction in LDL targets over time:
↪ Heart disease deaths fell almost 5x since 1950 as LDL targets tightened
No other disease has seen such a massive decrease in death rates, during that timeframe. Nothing else is even close, as the chart shows.
Annual death rates from heart disease have fallen by almost 5x since the 1950’s.
It used to be that over 500 out every 100,000 people in the USA died of heart disease each year. Now that number is down to almost 100.
The timing of the drops in death rates correlate strongly with the introduction of statins and the steadily more aggressive targets for lowering LDL.
This comment is from our group member, Dr. Adrian Mondry MD.
————-
Here's a correlation between published mortality rates for myocardial infarction (MI) and recommended LDL levels based on guidelines:
Mortality Rates for Myocardial Infarction:
- 1980-2000: 300-400 deaths per 100,000 population (pre-statin era)
- 2000-2010: 150-250 deaths per 100,000 population (early statin era)
- 2010-2020: 50-150 deaths per 100,000 population (contemporary statin era)
Recommended LDL Levels:
- 1985: National Cholesterol Education Program (NCEP) recommends LDL < 130 mg/dL
- 2001: NCEP ATP II recommends LDL < 100 mg/dL
- 2013: American College of Cardiology/American Heart Association (ACC/AHA) recommends LDL < 70-100 mg/dL for high-risk individuals
- 2019: European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) recommends LDL < 55-70 mg/dL for very high-risk individuals
Correlation:
- As recommended LDL levels decreased, mortality rates for MI also decreased.
- The most significant decline in mortality rates occurred between 2000-2010, coinciding with widespread statin adoption.
- Contemporary guidelines recommending more aggressive LDL lowering (< 55-70 mg/dL) may contribute to further reductions in MI mortality.
Studies:
- The Scandinavian Simvastatin Survival Study (1994): demonstrated 30% reduction in MI mortality with LDL lowering
- The PROVE-IT TIMI 22 trial (2004): showed 16% reduction in MI mortality with intensive LDL lowering
- The IMPROVE-IT trial (2015): demonstrated 2% absolute risk reduction in MI with ezetimibe + simvastatin
Guideline Evolution:
- 2020 ACC/AHA Guideline Update: emphasizes personalized risk assessment and LDL lowering
- 2021 ESC/EAS Guideline Update: recommends LDL < 50 mg/dL for extremely high-risk individuals
Limitations:
- Correlation does not imply causation.
- Other factors (e.g., lifestyle changes, improved medical therapy) contribute to declining MI mortality.
Sources:
- American Heart Association (AHA)
- American College of Cardiology (ACC)
- European Society of Cardiology (ESC)
- European Atherosclerosis Society (EAS)
- National Cholesterol Education Program (NCEP)
- Journal of the American College of Cardiology
- Circulation
- European Heart Journal
#cvddeathHD #statinsHD
